8+ hour, 22+ min ago   (194+ words) OncoDaily is a specialized news and information platform that provides daily updates on oncology research, treatments, clinical trials, and advancements in cancer care. It serves healthcare professionals, researchers, and patients by delivering timely and accurate insights into the latest developments…...

2+ day, 20+ hour ago   (208+ words) Liang Cheng, Director of Anatomic and Molecular Pathology at Brown Pathology and Laboratory Medicine, shared on LinkedIn: “In case you missed my earlier post, here’s the companion (twin!) comprehensive review on prostatic neuroendocrine tumors, published in Endocrine Pathology, written by…...

4+ day, 11+ hour ago   (50+ words) Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared on X: “Spot on talk by Xue-Yan Jiang immunotherapy as a double-edged sword. While IO revolutionises cancer care, managing irAEs remains key. We needed predictors, early clinical markers and…...

4+ day, 15+ hour ago   (88+ words) The Babak Lab shared on LinkedIn: “Merck and Moderna have announced positive top-line results from the Phase 3 INTerpath-001 trial of intismeran autogene (V940) + pembrolizumab in patients with resected high-risk melanoma. INTerpath-001 is the first positive Phase 3 trial of an individualized neoantigen…...

5+ day, 12+ hour ago   (126+ words) Lung Cancer Europe shared on LinkedIn: “Changes after immunotherapy starts may be more informative than a sample taken before treatment begins. New research published in Cancer Cell looked at how the tumour immune environment changes during checkpoint inhibitor treatment. The…...

5+ day, 16+ hour ago   (156+ words) Eleonora Dondossola, Assistant Professor in the Department of Genitourinary Medical Oncology – Research, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, shared on LinkedIn: “Big celebrations for my first R01! This funding will allow us to investigate…...

1+ week, 12+ hour ago   (219+ words) Marco Donia, Professor at CCIT-DK, shared by Marie Weitemeyer, PhD Fellow at Copenhagen University Hospital, on LinkedIn. “A small but real OS advantage in patients with resected stage III melanoma, treated with adjuvant anti-PD1 (note however all the limitations of…...

1+ week, 12+ hour ago   (188+ words) Alberto Puccini, Medical Oncologist at IRCCS Humanitas Research Hospital, shared on LinkedIn. “Our paper is out in Nature Reviews Gastroenterology and Hepatology! I am incredibly proud of Michela Bartolini, one of my first fellows, who, through a wonderful collaboration with…...

1+ week, 3+ day ago   (89+ words) Laurel Coons, Bioinformatics Analyst at BioSkryb Genomics, shared on LinkedIn: Instead of trying to make the immune system’s cancer-killing cells stronger, CRG-150 takes a different approach: genetically reprogramming a patient’s own regulatory T cells, cells that tumors can use to…...

1+ week, 3+ day ago   (145+ words) Iylon Precision Oncology shared on LinkedIn: CXorf67 is a protein involved in regulating gene activity and repairing damaged DNA. Abnormally high levels have been identified in several cancers, including certain brain, uterine, lung and skin cancers. Researchers believe that CXorf67 may contribute…...